Vident Advisory LLC Acquires New Stake in Aurinia Pharmaceuticals Inc $AUPH

Key Points

• Vident Advisory LLC has acquired a new stake in Aurinia Pharmaceuticals, purchasing 28,831 shares valued at approximately $232,000.
• Institutional investors now own 36.83% of Aurinia Pharmaceuticals, with several hedge funds increasing their positions in the company recently.
• Aurinia Pharmaceuticals reported $0.16 EPS in its latest quarterly earnings, missing analyst expectations by $0.01, despite revenue exceeding estimates at $70.01 million.

Vident Advisory LLC acquired a new stake in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 28,831 shares of the biotechnology company's stock, valued at approximately $232,000.

Several other hedge funds have also recently added to or reduced their stakes in the business. Tang Capital Management LLC grew its position in Aurinia Pharmaceuticals by 16.6% in the fourth quarter. Tang Capital Management LLC now owns 8,429,500 shares of the biotechnology company's stock worth $75,697,000 after buying an additional 1,200,000 shares during the last quarter. Nuveen Asset Management LLC grew its position in Aurinia Pharmaceuticals by 10.2% in the fourth quarter. Nuveen Asset Management LLC now owns 1,492,301 shares of the biotechnology company's stock worth $13,401,000 after buying an additional 138,054 shares during the last quarter. Nuveen LLC acquired a new position in Aurinia Pharmaceuticals in the first quarter worth approximately $10,014,000. Northern Trust Corp grew its position in Aurinia Pharmaceuticals by 5.9% in the fourth quarter. Northern Trust Corp now owns 1,054,365 shares of the biotechnology company's stock worth $9,468,000 after buying an additional 58,676 shares during the last quarter. Finally, Point72 Asset Management L.P. acquired a new position in Aurinia Pharmaceuticals in the fourth quarter worth approximately $7,630,000. Institutional investors and hedge funds own 36.83% of the company's stock.

Analyst Ratings Changes

Several research firms have issued reports on AUPH. Royal Bank Of Canada lifted their price target on shares of Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the stock an "outperform" rating in a research report on Friday, August 1st. HC Wainwright restated a "buy" rating and issued a $17.00 price target on shares of Aurinia Pharmaceuticals in a research report on Wednesday, July 30th. Three research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $12.00.

Insider Buying and Selling

In other news, Director Kevin Tang acquired 1,000,000 shares of the firm's stock in a transaction that occurred on Friday, August 1st. The stock was purchased at an average price of $10.12 per share, with a total value of $10,120,000.00. Following the purchase, the director owned 11,029,500 shares of the company's stock, valued at approximately $111,618,540. This trade represents a 9.97% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Over the last three months, insiders have purchased 1,300,000 shares of company stock valued at $13,590,000. Company insiders own 12.20% of the company's stock.

Aurinia Pharmaceuticals Trading Up 0.4%

Aurinia Pharmaceuticals stock opened at $12.35 on Wednesday. The company has a 50 day moving average price of $10.46 and a 200 day moving average price of $8.89. Aurinia Pharmaceuticals Inc has a 52 week low of $6.42 and a 52 week high of $12.82. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.63 and a current ratio of 5.23. The firm has a market capitalization of $1.63 billion, a price-to-earnings ratio of 28.72 and a beta of 1.26.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last posted its quarterly earnings data on Thursday, July 31st. The biotechnology company reported $0.16 EPS for the quarter, missing analysts' consensus estimates of $0.17 by ($0.01). Aurinia Pharmaceuticals had a return on equity of 20.06% and a net margin of 23.31%.The firm had revenue of $70.01 million during the quarter, compared to analyst estimates of $64.27 million. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. Research analysts forecast that Aurinia Pharmaceuticals Inc will post 0.11 EPS for the current year.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.